Medical Oncologist
After surgery
Residual disease after neoadjuvant chemo: what comes next
If invasive cancer was still present in the tissue removed at your operation, additional treatment is usually offered, chosen specifically because cancer remained. Identifying who needs more is the most useful thing giving chemotherapy before surgery produces. This page explains what is added for each subtype, and why older outcome figures no longer describe your situation.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Cancer was still there at surgery. What now?
- What is usually added, and why
- What happens between surgery and the next treatment
- The wording, in plain language
- How the same finding is read in different subtypes
- What this result does and does not mean
- What families take from this result
- Common questions about residual disease
The short answer
Cancer was still there at surgery. What now?
Additional treatment is usually offered, chosen specifically because cancer remained. This is the single most useful thing that giving chemotherapy before surgery produces: it identifies who needs more, and treatments now exist for exactly this situation.
What residual disease actually means
It means invasive cancer was found in the tissue removed at your operation. It does not mean the chemotherapy failed. Substantial shrinking is a real response even when it is not complete, and your report will usually grade how much was left.
It depends heavily on your subtype
In hormone sensitive, HER2 negative cancers, some disease remaining is the usual outcome and is not alarming. In triple negative and HER2 positive cancers it carries more weight, and it is in those groups that extra treatment is most clearly offered.
What comes next
What is usually added, and why
The treatment offered depends on your subtype. Ask specifically which applies to you.
If your cancer is triple negative
Further chemotherapy after surgery is commonly offered, given specifically because disease remained. This is a well established approach and your oncologist will explain the course.
If your cancer is HER2 positive
The HER2 treatment given after surgery is usually changed to a different one, rather than continuing what you had before. This is decided directly on the residual disease result.
Ask which HER2 treatment you are now on, and for how long.If your cancer is hormone sensitive
Hormone tablets are the mainstay and continue for years. For some women with higher-risk features an additional targeted tablet is added alongside them.
If you carry an inherited gene fault
Where a BRCA fault is present, a further targeted treatment may be offered after surgery. If you have not been tested and this applies, ask now rather than later.
Ask about testing if
- You were diagnosed young
- There is breast or ovarian cancer in the family
- Your cancer is triple negative
Not sure whether this applies to you?
Ask an oncologistThe order
What happens between surgery and the next treatment
-
The report comes back
Usually one to two weeks after surgery. It describes how much cancer remained in the breast and in the nodes, often graded as a response category.
-
Your case returns to the tumour board
The response result is exactly the kind of finding that is discussed jointly, because it changes what several specialists will each contribute.
-
The plan is explained to you
What is being added, why, how long it lasts and what the side effects are. Take someone with you, because this appointment carries a lot of information.
-
Treatment starts once you have healed
Usually a few weeks after the operation, so the wound settles first. Radiotherapy and the added treatment are sequenced by your team.
-
Longer-term treatment continues
Hormone tablets, where they apply, run for years afterwards. This is the part that most often lapses and the part that matters most over time.
On your report
The wording, in plain language
- Residual disease
- Invasive cancer still present in the tissue removed at surgery.
- Residual cancer burden, or RCB
- A grading of how much was left, from none through to extensive. Not every laboratory reports it.
- Adjuvant treatment
- Treatment given after surgery. Here it is chosen because of what the surgery found.
- Node positive after treatment
- Cancer still in the lymph nodes at surgery. It usually means the radiotherapy covers a wider area.
- Escalation
- The word your team may use for adding treatment on the basis of a poorer response.
- BRCA
- An inherited gene fault that raises breast and ovarian cancer risk, and that opens particular treatments.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Side by side
How the same finding is read in different subtypes
Your subtype
What residual disease usually leads to
Triple negative
Further chemotherapy after surgery is commonly offered
HER2 positive
The HER2 treatment after surgery is usually switched
Hormone sensitive, HER2 negative
An expected finding; hormone tablets do the long work
Any subtype with a BRCA fault
An additional targeted treatment may be offered
Being straight with you
What this result does and does not mean
Residual disease is associated with a higher risk of the cancer returning than a complete response, and your oncologist should say so plainly rather than talking around it. It is also the finding that now unlocks treatment designed for precisely this situation.
The numbers you find online are old
Outcome figures attached to residual disease largely predate the treatments now given because of it. They describe women who received nothing extra. Applying them to yourself understates where you actually stand.
It is not a failure, and not your fault
How a cancer responds is a property of its biology. It is not caused by diet, by stress, by a delayed cycle or by anything anyone in your family did. This is worth saying clearly, because the blame usually lands on the patient.
What to ask at the next appointment
What exactly was left, and was it graded. What are you adding because of it. What would you have offered if the response had been complete. How long does the extra treatment last. Is a trial open to me. Write them down beforehand.
Commonly believed
What families take from this result
Cancer left behind means the treatment failed.
Shrinking a tumour substantially is a real response, and in hormone sensitive cancers a partial response is what is expected. Failure would mean growth during treatment. What you have is information that is now shaping a better plan.
The survival figures I found apply to me.
Almost all of those figures describe women who received nothing extra after surgery, because the treatments given for exactly this result did not exist when the data were collected. Applying them to yourself understates where you actually stand.
We should have operated first after all.
Operating first would have left the same cancer with the same biology, and nobody would have known it responded poorly. The extra treatment you are now being offered is available precisely because the response was measured.
More treatment means the situation is desperate.
It means the situation is understood well enough to act on. Treatment added on the basis of residual disease is given with the intention of clearing the cancer completely, not as a last resort.
Questions we are asked
Common questions about residual disease
Does this mean the chemotherapy failed?
No. Substantial shrinking is a real response even when some cancer remains, and in hormone sensitive cancers a partial response is the expected outcome. Failure would mean growth during treatment, which is a different finding your team would have acted on at the time.
Is more chemotherapy definitely needed?
It depends on your subtype and on how much was left. It is commonly offered in triple negative disease. In hormone sensitive cancers it is often not, because tablets do the long-term work. Ask what is being recommended for you specifically and why.
Should I have had a different treatment from the start?
There is no way to know in advance which cancers will clear completely, which is precisely why this order of treatment is used. The response could not have been predicted, and the information it gave is now shaping what you receive.
Does it change my radiotherapy?
It can. Where cancer remained in the lymph nodes, the treated area often includes the armpit and the region above the collarbone rather than the breast alone. Your radiation oncologist will explain which areas your plan covers.
Should I be tested for a BRCA gene fault?
Ask, particularly if you were diagnosed young, if your cancer is triple negative, or if there is breast or ovarian cancer in your family. A positive result can open a further targeted treatment after surgery, so the timing of testing matters.
Can I ask for a trial?
Yes, and this is one of the situations where trials are most actively recruiting. Ask what is open at your centre and whether a referral elsewhere is worth considering. Do it before the treatment after surgery is finalised, because eligibility often depends on the sequence.
How much extra treatment will I need?
It varies from a defined course of further chemotherapy to a change of tablet taken for a year or more. Ask for the schedule in writing, including how many cycles or months, so you can plan work and family around it.
Am I likely to relapse?
Your risk is higher than with a complete response, and lower than the older published figures suggest, because those describe women who received no additional treatment. Ask your own oncologist rather than reading general numbers, since the answer depends heavily on your subtype and on what is being added.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Cancer Research UK — Treatment after breast cancer surgery
- National Cancer Institute — Breast cancer treatment (PDQ)
- Breast Cancer Now — Treatment after surgery
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.